07.07.15
Ecouen, France-based Vygon SA has acquired French firm Perouse Medical, which makes cardiovascular medical devices.
Perouse specializes in stents; vascular grafts and patches; radial compression and inflation systems; hemostatic valves; angiographic syringes; fluid management consumables for contrast media injectors for scanners and magnetic resonance imaging; and long-term vascular access devices (implantable ports, peripherally inserted central catheters, Huber needles, and catheter maintenance dressings.
Financial terms of the agreement were not disclosed.
Established in 1984, Perouse Medical had sales of $31.4 million in 2014. It has a presence in 90 countries and a network of 200 distributors, according to Vygon. Roughly 55 percent of Perouse Medical’s business stems from its international operations. With French offices in the Oise region and in the Greater Lyon area of the Rhône-Alpes region, the company employs 336 people. Perouse Medical will be the cardiovascular and long-term vascular access specialist within the Vygon group. Thomas Walter, the current deputy director general of Perouse Medical, will be responsible for the general management of the company and will join the Vygon Group’s executive committee.
This operation is in line with Vygon’s development plan and is primarily intended to reinforce the existing product ranges. With this acquisition, Vygon strengthens its position in the adult long-term vascular access market, which the company estimates is worth $1.2 billion.
The operation also aims to develop expertise on new single-use health product families, with a focus on interventional cardiology and the treatment of cardiovascular diseases.
Perouse Medical’s patent portfolio, with 162 patents, will become the property of Vygon.
“With this new acquisition, Vygon consolidates its position in the French and international markets, thereby demonstrating its determination to achieve by 2022 the objectives set out in its growth plan,” said Stéphane Regnault, chairman of Vygon’s board of management. “Perouse Medical is renowned amongst health professionals for its strong expertise, the quality of its medical devices and its capacity for innovation. For these reasons, Perouse is a perfect fit for the Vygon Group development strategy.”
Founded in 1962, Vygon designs, manufactures and markets high-tech single-use medical devices for healthcare professionals in hospital and for private and independent practitioners. Vygon makes products in a number of clinical specialties: neonatology, adult and pediatric critical care, anesthesia, oncology, emergency, surgery and home care. The company distributes more than 200 million products a year in more than 100 countries through its network of 25 subsidiaries and 79 distributors. Vygon products have CE mark or U.S. Food and Drug Administration clearance and are manufactured in the group’s eight factories in Europe, the United States and Colombia.
Vygon employs 1,800 staff worldwide. Revenue in 2014 was $285 million, with 81 percent of sales derived from Vygon’s international business.
Perouse specializes in stents; vascular grafts and patches; radial compression and inflation systems; hemostatic valves; angiographic syringes; fluid management consumables for contrast media injectors for scanners and magnetic resonance imaging; and long-term vascular access devices (implantable ports, peripherally inserted central catheters, Huber needles, and catheter maintenance dressings.
Financial terms of the agreement were not disclosed.
Established in 1984, Perouse Medical had sales of $31.4 million in 2014. It has a presence in 90 countries and a network of 200 distributors, according to Vygon. Roughly 55 percent of Perouse Medical’s business stems from its international operations. With French offices in the Oise region and in the Greater Lyon area of the Rhône-Alpes region, the company employs 336 people. Perouse Medical will be the cardiovascular and long-term vascular access specialist within the Vygon group. Thomas Walter, the current deputy director general of Perouse Medical, will be responsible for the general management of the company and will join the Vygon Group’s executive committee.
This operation is in line with Vygon’s development plan and is primarily intended to reinforce the existing product ranges. With this acquisition, Vygon strengthens its position in the adult long-term vascular access market, which the company estimates is worth $1.2 billion.
The operation also aims to develop expertise on new single-use health product families, with a focus on interventional cardiology and the treatment of cardiovascular diseases.
Perouse Medical’s patent portfolio, with 162 patents, will become the property of Vygon.
“With this new acquisition, Vygon consolidates its position in the French and international markets, thereby demonstrating its determination to achieve by 2022 the objectives set out in its growth plan,” said Stéphane Regnault, chairman of Vygon’s board of management. “Perouse Medical is renowned amongst health professionals for its strong expertise, the quality of its medical devices and its capacity for innovation. For these reasons, Perouse is a perfect fit for the Vygon Group development strategy.”
Founded in 1962, Vygon designs, manufactures and markets high-tech single-use medical devices for healthcare professionals in hospital and for private and independent practitioners. Vygon makes products in a number of clinical specialties: neonatology, adult and pediatric critical care, anesthesia, oncology, emergency, surgery and home care. The company distributes more than 200 million products a year in more than 100 countries through its network of 25 subsidiaries and 79 distributors. Vygon products have CE mark or U.S. Food and Drug Administration clearance and are manufactured in the group’s eight factories in Europe, the United States and Colombia.
Vygon employs 1,800 staff worldwide. Revenue in 2014 was $285 million, with 81 percent of sales derived from Vygon’s international business.